

FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 2C




FIGURE 2D




FIGURE 2E




FIGURE 2F




FIGURE 2G




FIGURE 2H




FIGURE 2I




FIGURE 2J




FIGURE 2K




FIGURE 2L




FIGURE 2M




FIGURE 2N




FIGURE 20




FIGURE 2P




FIGURE 2Q




FIGURE 2R




FIGURE 2S




FIGURE 2T

Title: Compositions and Methods Comprising Protein
Activated Receptor Antagonists
Inventor: Todd A. Hembrough
Atty Docket: 05213-3041 (43170-286877)




FIGURE 2U




FIGURE 2V




FIGURE 2W




FIGURE 2X




FIGURE 2Y




FIGURE 2Z




FIGURE 2AA

Title: Compositions and Methods Comprising Protein
Activated Receptor Antagonists
Inventor: Todd A. Hembrough
Atty Docket: 05213-3041 (43170-286877)




FIGURE 2BB

Title: Compositions and Methods Comprising Protein
Activated Receptor Antagonists
Inventor: Todd A. Hembrough
Atty Docket: 05213-3041 (43170-286877)




FIGURE 2CC




FIGURE 3




FIGURE 4A




FIGURE 4B




FIGURE 4C




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16

FIGURE 17





FIGURE 18



	animal #	weight (g)		tarsal, left (mm)		tarsal, right (mm)	
		Day 1	Day 8	Day 1	Day 8	Day 1	Day 8
untreated, no arthritis	337	23.1	23.7	2.67	2.79	2.72	2.72
	338	23.8	24.6	2.73	2.68	2.49	2.41
	339	21.3	22.7	2.72	2.83	2.54	2.46
	340	20.9	22.4	2.67	2.69	2.62	2.68
	341	23.7	25	2.88	2.95	2.7	2.75
		22.6	23.7	2.73	2.79	2.61	2.60
			1.1		0.05		-0.01
PBS, arthritis	317	22	17.3	2.71	3.99	2.7	3.6
	318	21.3	18.1	2.66	4.57	2.58	3.55
	319	22.5	21.7	2.65	3.11	2.63	2.81
	320	21.8	17.7	2.74	3.94	2.75	3.83
	321	23.6	17.5	2.75	3.81	2.63	3.7
		22.2	18.5	2.70	3.88	2.66	3.50
			-3.8		1.18		0.84
2ME2, arthritis	352	23.4	20.9	2.74	3.1	2.73	3.39
	353	22.4	19.5	2.81	3.29	2.75	3.18
	354	22.8	18.1	2.62	2.51	2.68	2.91
	355	21.5	20.4	2.72	3.07	2.66	2.81
	356	20.7	21.2	2.75	2.73	2.63	3.42
		22.2	20.0	2.73	2.94	2.69	3.14
			-2.1		0.21		0.45
547, arthritis	327	22.5	17.9	2.64	3.35	2.69	3.36
	328	22	17.1	2.73	3.37	2.74	3.17
	329	21.5	20.4	2.7	3.03	2.67	3.48
	330	20.6	18.2	2.62	3.24	2.65	3.24
	331	23.2	19	2.58	3.2	2.65	3.31
		22.0	18.5	2.65	3.24	2.68	3.31
			-3.4		0.58		0.63
LIGK, arthritis	322	21.9	24.3	2.69	2.88	2.56	3.02
	323	21.6	22.3	2.75	2.9	2.65	2.65
	324	22.8	23.5	2.68	3.01	2.71	2.89
	325	23.4	23.1	2.62	2.91	2.75	2.94
	326	21	21.6	2.74	2.81	2.69	2.97
		22.1	23.0	2.70	2.90	2.67	2.89
			0.8		0.21		0.22
							0.43

FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22

Title: Compositions and Methods Comprising Protein
 Activated Receptor Antagonists
 Inventor: Todd A. Hembrough
 Atty Docket: 05213-3041 (43170-286877)

	LIGK Dose	T/C			5-47 Dose	T/C
gms02-19	4000	0.44			1000	0.44
met	2000	0.52		met	500	0.46
					250	0.87
gms02-13	4000	0.27				
met	2000	0.65				
	1000	0.81				
gms02-07	1000	0.77				
met	500	0.83				
	500 bid	0.43				
gms02-004	1000	0.38				
primary	500	0.65				
gms02-028	4000	0.56		Primary	4000	1
primary					2000	1.05
					1000	1.3
gms01-xx	1000	0.38,,0.65				
met						

FIGURE 23




FIGURE 24

020626 Inhibition of Ca^{++} Signalling by 5mM LIGK Lots, Fragments,
 Scrambled, and Reverse Peptides
 HT29, 67uM AP2




FIGURE 25